University Research Commercialisation

The Australian Government is undertaking a scoping study to understand how to best implement a University Research Commercialisation Scheme to better translate and commercialise university research outputs. It has appointed an Expert Panel and issued a Discussion Paper.

Research Australia’s response to the Discussion Paper addresses the role of ‘Missions’, the use of stage-gating and the role of co-funding by Governments, universities and industry. It highlights the critical need to better align existing funding programs and fill the gaps to provide a more seamless approach to research funding from basic research through to commercialisation.

Research Australia’s submission is available here.

2021 Pre Budget submission calls for renewed investment in R&D

Research Australia’s Pre Budget submission to the Treasurer ahead of the 2021 Budget  focuses on the vital role of health and medical research and innovation in Australia’s  response to the COVID-19 pandemic, and the manufacturing and innovation opportunities that health and medical research presents for Australia’s economic recovery.

It calls for renewed investment in R&D by the Australian Government, continued support for universities and medical research institutes with meeting indirect research costs, and measures to support medical products R&D and manufacture. The case for increasing NHMRC and ARC funding is also made. Funding for Government initiatives in data sharing and preventive health are among other measures sought.

Research Australia’s submission is available here.

Improving approval processes for new drugs and medical technologies

Research Austrlaia has responded to the Parliamentary Inquiry into the Approval Processes for New Drugs and Medical Technologies.

Opportunities exist to change our approval processes to benefit patients and better support research and development in Australia. Faster and more effective approval processes mean new medicines and technologies reach patients faster. Improving the environment for clinical trials enables Australian patients to benefit from the latest medicines and technologies developed overseas while also helping Australian health and medical research to flourish in a competitive and lucrative world market. Research Australia’s submission identifies some of these opportunities with the twin objectives of improving Australians’ health and prosperity.

Research Austrlaia’s submission is available here.

The Committee is expected to hold public hearings in early 2021.

Aged Care Research is essential for a better Aged Care system

Research Australia is delighted that research is firmly on the agenda for the Royal Commission into Aged Care Quality and Safety.

The peak body’s Chief Executive Nadia Levin welcomed the news that among the more than 100 recommendations made by counsel to the Commissioners, were several very important recommendations relating to research.

Importantly, Counsel has recommended establishing a dedicated Aged Care Council to set a strategy and agenda for research and development into aged care. A dedicated aged research fund with an annual budget of 1.8% of government expenditure on aged care has also been recommended.

‘This would be a welcome boost to aged care research in Australia and has the potential to lead to better, higher quality and safer care, said Ms Levin. ‘In fact, I don’t think this promise of a better system can be delivered without more research, it is absolutely essential.’

Research Australia has made the case on several occasions for increasing research into aged care and ageing. We urged the inclusion of research in the Commission’s original terms of reference and have liaised with the Commission’s officers to connect them with researchers who were able to assist the Inquiry.

The aim is to prioritise research that involves co-design with older people, their families and the aged care workforce, and to facilitate networks between researchers, industry and government. The scope of research is broad, encompassing technology pilots and innovation projects, and assisting the translation of research into practice to improve aged care.

In a series of related recommendations, data collection across aged care should be improved and a national minimum aged care dataset developed under the auspice of the Australian Institute for Health and Welfare.

The Commissioners are now considering the evidence they have received and are due to provide their final report to the Australian Government by the end of February next year. (They may accept, reject or modify Counsel’s recommendations.) More information about the Royal Commission, including the final submissions, is available here.

Research Australia will continue its advocacy focus along with its members such as NARI, CSIRO, University of Queensland, Flinders University and the University of Wollongong to keep research firmly on the agenda as the Royal Commission considers its response.

Please join our efforts through contributing to Research Australia’s submission due on the 12th November via greg.mullins@researchaustralia.org

 

Budget Update 2020

Summary

The global economic impact of COVID-19 has been the overwhelming influence on the Budget handed down tonight. This is a big spending Budget, the biggest Australia has seen, focused on providing immediate stimulus to the economy but also laying the foundations for a future Australia, shaped by the lessons of the last nine months.

Most relevant to health and medical research are the following key announcements:

    • Last year’s forecast budget spending on health for 2020-21 was $82.5 billion. This forecast has been revised up to $115.5 billion, as we begin to see just how much COVID-19 is driving up healthcare costs. In the coming months and years, Australians will look to health and medical research and innovation to deliver more effective treatments and more efficient pathways of care to curtail these costs. Research Australia will continue to work with Government to ensure support for the crucial role all parts of the health and medical research pipeline have to play in delivering better, more sustainable care.
    • An extra $1 billion this financial year through the Research Support Program for our university researchers will be critical to maintaining Australia’s national health and medical research capability. More than half of all Australian health and medical research in Australia is undertaken in the higher education sector. It is clear that Australia can no longer rely so heavily on international student fees to subsidise research. In the long term, we need to look at effective partnerships between higher education, government, industry and philanthropy. The commitment in this Budget to supporting university research jobs is a welcome interim step towards establishing a more sustainable higher education sector.
    • The Government will restore an additional $2 billion over 4 years through the Research and Development Tax Incentive to help innovative businesses that invest in research and development. It is doing this by reversing some of the changes to the R&DTI legislation that are currently before the Senate.
    • The budgets for the NHMRC and MRFF remain virtually unchanged. At the same time, researchers are dealing with extra costs to their funded project due to the delays and disruptions caused by COVID-19. While the universities benefit from the one-off increase in the Research Support Program, there is no similar support for researchers in Medical Research Institutes. Research Australia remains concerned that NHMRC funding has not increased over the forward estimates to keep pace with inflation, with the net effect that NHMRC funding continues to decline in real terms.

Broader Context:

One of the key lessons from the COVID-19 pandemic is that we have become overly reliant on global supply chains for vital materials. This is driving a new focus on manufacturing and there are new roadmaps being developed which will, hopefully, join the dots between research, product development and manufacturing more successfully than has been done in the past. $1.3 billion over five years from 2020-21 will establish the Modern Manufacturing Initiative to: support manufacturing projects focused on building long-term business collaboration at scale; translating research into commercial outcomes and bringing new products to market; and integrating local firms to deliver products and services into global value chains. New roadmaps to guide the Modern Manufacturing Strategy are due in time for the 2021 Budget, in six months’ time, including for medical products.

Manufacturing accounts for around 6% of Australia’s economic output but is responsible for a quarter of all industry spending on R&D. However, Australia’s business spending on R&D is low by world standards. If Australia is to achieve the objectives of the Modern Manufacturing Strategy this will have to change, and we have to better connect business with Australia’s powerhouses of research, our universities and medical research institutes.

The Government has made several attempts to reform the R&D Tax Incentive in recent years, and tonight’s Budget is no exception. The R&DTI is critical to increasing business expenditure on R&D in Australia, and thus to the Modern Manufacturing Strategy. The Government is reversing several of the measures which are currently sitting before the Senate. For small business, the $4 million cap goes, and the rate is fixed at 18.5% above the company tax rate. For large companies the number of tiers in the intensity threshold will be reduced to two, with the RDTI paid at a rate 8.5% and 18.5% above the company’s tax rate for tiers one and two respectively. This is expected to increase the amount of R&DTI paid to industry by $2 billion over the forward estimates, compared to the amounts that would have been paid if the legislation had been amended in accordance with the Government’s previous plan.

 

Continue reading “Budget Update 2020”

Pre Budget submission calls for renewed investment in R&D (December 2019)

Research Australia’s submission to the Treasurer ahead of the 2020-21 Budget has used the Government’s own figures showing a drop in R&D investment by Government and business to call for a renewed focus on research and development, including health and medical research. In addition to greater investment in R&D across the board, Research Australia has called for increased funding for the research programs of the NHMRC and ARC; action to make better use of data; and investment in prevention.

To read Research Australia’s submission and the full list of recommendations, click here.

Improving Research Funding

Research Australia’s submission to the Parliamentary Inquiry into Research Funding has proposed a review across all funding agencies and government departments to eliminate unnecessary inconsistencies in application guidelines, processes and acquittal procedures. We also called for the development of a common approach to the calculation and payment of funding to cover the indirect costs of research.

Research Australia’s submission

Peer Review- 2 Stage Process for Idea Grants

Research Australia’s submission in response to the NHMRC’s Peer Review Consultation has urged the NHMRC to consult further on options for a two stage application process for the Ideas Grants.

There is considerable interest within our membership and across the health and medical research sector in a two-stage application process, and while there is not yet agreement on the approach, there is an appetite for change. Research Australia believes that a two-stage application process for Ideas Grants, incorporating an abbreviated application at the first stage, provides the chance to reduce the burden on applicants and reviewers alike, while better supporting the objectives of Ideas Grants to promote innovative and novel research.

In particular, the process could provide the focus on novel and innovative ideas and reduced emphasis on track record that the NHMRC is seeking.  Research Australia’s submission explores the opportunity to adopt a two-stage application process for Ideas Grants and puts forward some considerations for further investigation and consultation.

Research Australia’s submission

Federal Medical Research Plan: The Health & Economic Roadmap We Need

Media Release: Wednesday, 9 November 2016

Link to the MRFF Strategy & Priorities.

With almost two in three Australian adults and one in four children overweight or obese, two-thirds of Australians over the age of 50 with poor bone density, and one in six Australians with chronic back pain, tonight’s release of the Medical Research Future Fund (MRFF) Strategy sets out the roadmap for addressing some of our biggest health issues.

That is the verdict from the medical research community and Research Australia, the organisation behind the virtual doubling of health (NHMRC) funding in 2000, and again in 2005.

“As the organisation that has been championing health and medical research for the last 15 years, we can tell you the MRFF is a real game changer,” said Research Australia Chair, Dr Christine Bennett.

CEO of Research Australia, Nadia Levin said the MRFF Strategy’s vision of a health system informed by quality research is exactly what’s needed.

“Research Australia shares the Strategy’s vision of a health system fully informed by quality health and medical research,” said Levin.

Continue reading “Federal Medical Research Plan: The Health & Economic Roadmap We Need”

Review of research policy and funding for Higher Education

Research Australia’s submission to the review of research policy and funding arrangements emphasises that the primary role of universities is the creation of new knowledge and that the application of new knowledge (of which commercialisation is one of the paths) is important but necessarily a secondary role. Programmes such as the Research Block Grants and the competitive grants programmes must maintain a primary focus on research. There is scope to simplify and improve these programmes and to better support innovation in research training.

Review of research policy and funding for Higher Education